Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
نویسندگان
چکیده
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence "MAbImprove," the GDR 3260 "Antibodies and therapeutic targeting," and the Grant Research program ARD2020 "Biotherapeutics" invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 - April 1, 2016 in Tours, France.
منابع مشابه
Monoclonal Antibodies as Therapeutic Agents: Advances and Challenges
Despite the major advances in conventional forms of treatment (i.e. surgical techniques, radiotherapy and chemotherapy) and improved survival rates, cancer is still the second leading cause of death in developing countries. One major limitation of cytotoxic drugs and radiation in the treatment of cancer patients is their inability to discriminate between malignant and normal tissues. This in tu...
متن کاملGenetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy
Professional Institutional Original Effective Date: March 26, 2012 Original Effective Date: March 26, 2012 Revision Date(s): April 8, 2013; December 31, 2013; March 31, 2015; January 1, 2016; February 17, 2016; January 1, 2017; April 12, 2017; January 1, 2018 Revision Date(s): April 8, 2013; December 31, 2013; March 31, 2015; January 1, 2016; February 17, 2016; January 1, 2017; April 12, 2017; ...
متن کاملTherapeutic antibodies and infectious diseases, Tours, France, November 20−22, 2012
The Therapeutic Antibodies and Infectious Diseases international congress was held in Tours, France on November 20-22, 2012. The first session was devoted to the development of antibodies directed against bacterial toxins or viruses that could be used in a potential bioterrorist threat situation. The second session dealt with the effector functions of anti-microbial antibodies, while the third ...
متن کاملTherapeutic Applications of Monoclonal Antibodies in Multiple Sclerosis
Despite the various therapies available, the use of monoclonal antibodies is a highly specific approach that has only recently been of interest to researchers. The properties of antibodies have led to their use in the treatment of various diseases, including cancer, Alzheimer's disease, diabetes and multiple sclerosis (MS). MS, a chronic inflammatory disease, occurs commonly in young adults. Th...
متن کاملAntibody biosimilars: Fears or opportunities?
The industrial workshop “Antibody biosimilars” was opened by Hervé Watier (CNRS UMR 7292, Université FrançoisRabelais de Tours, France), coordinator of the MAbImprove Laboratory of Excellence. He delivered his welcome address, starting with a quick recall of the LabEx MAbImprove story. This LabEx was created in 2011 and funded by “Investment for the Future” program (French “Big Loan”). He then ...
متن کامل